dromlakhani Noveltreat (Semaglutide 0.25 / 0.5 / 1 / 1.7 / 2.4 mg) — Prescribing Guide
Indication (adults)
Adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in:
- BMI ≥ 30 kg/m² (obesity), OR
- BMI ≥ 27 kg/m² (overweight) with ≥ 1 weight-related comorbidity — hypertension, type 2 diabetes, or dyslipidemia.
Maintenance dose: 2.4 mg once weekly (SC).
Contraindications
- Hypersensitivity to semaglutide or excipients
- Pregnancy
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)
- History of pancreatitis
Dose Escalation (once-weekly SC, every 4 weeks)
| Week | Weekly dose |
|---|---|
| 1–4 | 0.25 mg |
| 5–8 | 0.5 mg |
| 9–12 | 1.0 mg |
| 13–16 | 1.7 mg |
| 17 + | 2.4 mg (maintenance) |
- Escalate every 4 weeks to improve GI tolerance.
- Continue the highest tolerated effective dose; adjust background insulin or sulfonylurea if co-prescribed.
Missed Dose
- Take within 5 days of the scheduled day → administer, then resume the regular weekly schedule.
- > 5 days late → skip; resume on the next scheduled day.
- Changing injection day: ensure ≥ 48 h between the last dose and the new day.
Administration
- Subcutaneous injection — abdomen, thigh, or upper arm. Rotate sites.
- Same day each week; any time of day, with or without food.
- Single-use pre-filled pen — needle is hidden and pen auto-locks after use.
Special Populations
| Population | Adjustment |
|---|---|
| Hepatic impairment | No dose adjustment |
| Renal impairment (mild–severe) | No dose adjustment; caution on initiation and escalation |
| Dialysis (HD or PD) | No dose adjustment recommended; evidence limited — use caution |
| Pregnancy / breastfeeding | Contraindicated |
Warnings and Precautions
- Pancreatitis — immediate cessation if suspected. Do not resume if confirmed.
- Diabetic retinopathy — monitor closely in patients with a prior history.
- Hypoglycemia risk with insulin or sulfonylurea → lower the dose of the secretagogue or insulin before or at initiation.
- Renal function — monitor in renal impairment if severe GI reactions (vomiting, diarrhoea, dehydration) occur.
- Hypersensitivity — discontinue if suspected; seek medical advice promptly.
Drug Interactions
| Interaction | Effect | Action |
|---|---|---|
| ↓ Gastric emptying | Delayed absorption of oral drugs | Monitor narrow-therapeutic-index drugs |
| + Insulin / sulfonylurea | ↑ hypoglycemia risk | Reduce insulin or SU dose |
| Other GLP-1 RA / tirzepatide | Redundant mechanism | Avoid combination (contraindicated) |
| β-blockers, MAOIs, SSRIs, quinolones, salicylates, antidiabetics | ↑ hypoglycemic effect | Monitor glucose |
| Furosemide, thiazides, ritodrine | ↓ glycemic efficacy | Monitor glucose |
| Levothyroxine | ↑ serum levels | Monitor thyroid function |
Adverse Effects
- GI (most common): nausea, vomiting, diarrhoea, constipation, abdominal pain.
- Dizziness, mild tachycardia, headaches, dyspepsia, infections.
- Injection-site reactions; rare anaphylaxis.
- Low intrinsic risk of hypoglycemia and acute kidney injury.
Red Flags — When to Stop Noveltreat
- Persistent severe GI intolerance
- Symptoms suggesting pancreatitis (abdominal pain with nausea/vomiting)
- Vision changes (possible retinopathy)
- Thyroid nodule or dysphonia — evaluate for MTC
- Serum calcitonin > 50 ng/L — evaluate further for MTC; evaluate thyroid nodules on exam or neck imaging
Overdose
- Signs: severe nausea, vomiting, hypoglycemia.
- No specific antidote. Supportive care based on clinical presentation.
- Prolonged observation may be needed — half-life ~1 week; drug remains in circulation ~5 weeks after the last dose.
Cross-References
- Storage and pen handling →
noveltreat-storage-handling - Matching a patient to trial evidence →
noveltreat-patient-profile-matcher - Insulin / SU dose reduction on initiation →
glp1-insulin-su-dose-reduction - GI adverse-event management →
glp1-gi-ae-symptom-advisor,glp1-gi-ae-pharmacological-rescue,glp1-dose-escalation-troubleshooter - Pancreatobiliary monitoring →
glp1-pancreatobiliary-risk-monitor - Pre-procedure / perioperative →
glp1-perioperative-aspiration,glp1-endoscopy-pre-procedure
Reference
Sun Pharmaceutical Industries Ltd. Product Monograph — Diabetes and Obesity (Sematrinity® and Noveltreat®), 2026 (Data on file).